Malignant phyllodes tumor of the breast with rapid progression: a case report.
Breast
Chemotherapy
Doxorubicin–ifosfamide
Malignant phyllodes tumor
Mastectomy
Journal
Surgical case reports
ISSN: 2198-7793
Titre abrégé: Surg Case Rep
Pays: Germany
ID NLM: 101662125
Informations de publication
Date de publication:
07 Dec 2020
07 Dec 2020
Historique:
received:
20
03
2020
accepted:
18
09
2020
entrez:
7
12
2020
pubmed:
8
12
2020
medline:
8
12
2020
Statut:
epublish
Résumé
Malignant phyllodes tumors (PTs) of the breast occur infrequently and are difficult to treat with adjuvant therapy. Here, we present a case of a female patient with a huge malignant PT with rapid progression in a short period. A 44-year-old woman presented to our hospital with a rapid growth mass in her right breast, measuring 20 cm. She was initially diagnosed as having a borderline phyllodes tumor by core needle biopsy and underwent total mastectomy and artificial dermis was grafted, 20 days later, latissimus dorsi muscle flap and free skin grafting were performed. Two courses of doxorubicin-ifosfamide therapy were administered because of recurrence, but the patient died 4 months after the mastectomy. A standard therapeutic strategy for malignant PTs is needed in urgently to reduce the risk of tumor recurrence.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant phyllodes tumors (PTs) of the breast occur infrequently and are difficult to treat with adjuvant therapy. Here, we present a case of a female patient with a huge malignant PT with rapid progression in a short period.
CASE PRESENTATION
METHODS
A 44-year-old woman presented to our hospital with a rapid growth mass in her right breast, measuring 20 cm. She was initially diagnosed as having a borderline phyllodes tumor by core needle biopsy and underwent total mastectomy and artificial dermis was grafted, 20 days later, latissimus dorsi muscle flap and free skin grafting were performed. Two courses of doxorubicin-ifosfamide therapy were administered because of recurrence, but the patient died 4 months after the mastectomy.
CONCLUSIONS
CONCLUSIONS
A standard therapeutic strategy for malignant PTs is needed in urgently to reduce the risk of tumor recurrence.
Identifiants
pubmed: 33284362
doi: 10.1186/s40792-020-00986-8
pii: 10.1186/s40792-020-00986-8
pmc: PMC7721958
doi:
Types de publication
Journal Article
Langues
eng
Pagination
308Références
Int J Surg Case Rep. 2015;8C:161-5
pubmed: 25697402
Breast J. 2007 Nov-Dec;13(6):551-6
pubmed: 17983394
World J Surg Oncol. 2015 Feb 27;13:81
pubmed: 25880837
Chin J Cancer. 2014 Oct;33(10):492-500
pubmed: 25104281
Breast Cancer. 2010;17(1):29-34
pubmed: 19434472
Am J Pathol. 2000 Mar;156(3):1093-8
pubmed: 10702425
Int J Surg Case Rep. 2020;66:350-355
pubmed: 31927226
Histopathology. 2008 Jan;52(1):45-57
pubmed: 18171416
Am Surg. 2007 Oct;73(10):967-9
pubmed: 17983058
ISRN Surg. 2013;2013:361469
pubmed: 23577269
Ann Surg Oncol. 2007 Oct;14(10):2961-70
pubmed: 17562113
Surg Case Rep. 2015 Dec;1(1):121
pubmed: 26943445
J Natl Compr Canc Netw. 2007 Mar;5(3):324-30
pubmed: 17439760
World J Surg. 2016 Feb;40(2):323-8
pubmed: 26464157
Surg Oncol. 2003 Jul;12(1):27-37
pubmed: 12689668
Ann Ital Chir. 2012 Jul-Aug;83(4):331-6
pubmed: 22610081
Br J Plast Surg. 2000 Dec;53(8):659-66
pubmed: 11090321
Acta Chir Belg. 2015 Jan-Feb;115:27-32
pubmed: 26021788
Case Rep Oncol Med. 2019 Jun 18;2019:2759650
pubmed: 31316848